# Tri-modality therapy in advanced esophageal carcinoma: long-term results and insights from a developing world, institutional cohort.

**Tumor:** Cáncer de esófago
**Autores:** Chufal KS
**Revista:** Br J Radiol (2023)
**PMID:** 36541255 | **PMCID:** PMC9975378
**DOI:** [10.1259/bjr.20220413](https://doi.org/10.1259/bjr.20220413)
**Fuente:** PubMed Central (open access)

## Relevancia
Cáncer de esófago/UGE tras quimiorradioterapia CROSS o quimioterapia FLOT: aborda pCR ganglionar, supervivencia según yp-stage y patrones de diseminación nodal. Análogo a mama: el ypN0 es el factor pronóstico independiente más robusto tras tratamiento neoadyuvante.

## Abstract
To evaluate treatment outcomes in patients with esophageal carcinoma who underwent esophagectomy after neoadjuvant chemoradiation (NACRT/S). 254 patients met our inclusion criteria. The median OS was 71.4 months, RFS did not reach the median, and pCR rate was 46%. On multivariable Cox regression, BMI and absence of out-of-field node with extranodal extension influenced OS and RFS. Age, nodal stage and adventitial involvement also influenced OS. NACRT/S is feasible and effective. Out-of-field ENE merits further investigation as a prognostic factor.

## Acceso
Disponible en PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC9975378/

---
*Datos de PubMed. Citar: doi 10.1259/bjr.20220413*
